Papaverine Hydrochloride is a human prescription drug labeled by 'Oryza Pharmaceuticals Inc.'. National Drug Code (NDC) number for Papaverine Hydrochloride is 72516-024. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Papaverine Hydrochloride drug includes Papaverine Hydrochloride - 30 mg/mL . The currest status of Papaverine Hydrochloride drug is Active.

Papaverine hydrochloride papaverine hydrochloride papaverine hydrochloride papaverine edetate disodium sodium citrate citric acid monohydrate water

Indications and usage papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic.

General papaverine hydrochloride injection, usp, should not be added to lactated ringer’s injection, because precipitation would result. papaverine hydrochloride should be used with caution in patients with glaucoma. the medication should be discontinued if hepatic hypersensitivity with gastrointestinal symptoms, jaundice, or eosinophilia becomes evident or if liver function test values become altered.

Dosage and administration papaverine hydrochloride may be administered intravenously or intramuscularly. the intravenous route is recommended when an immediate effect is desired, but the drug must be injected slowly over the course of 1 or 2 minutes to avoid uncomfortable or alarming side effects. parenteral administration of papaverine hydrochloride in doses of 1 to 4 ml is repeated every 3 hours as indicated. in the treatment of cardiac extrasystoles, 2 doses may be given 10 minutes apart.

Contraindications intravenous injection of papaverine is contraindicated in the presence of complete atrioventricular heart block. when conduction is depressed, the drug may produce transient ectopic rhythms of ventricular origin, either premature beats or paroxysmal tachycardia. papaverine hydrochloride is not indicated for the treatment of impotence by intracorporeal injection. the intracorporeal injection of papaverine hydrochloride has been reported to have resulted in persistent priapism requiring medical and surgical intervention.

Adverse reactions the following side effects have been reported: general discomfort, nausea, abdominal discomfort, anorexia, constipation or diarrhea, skin rash, malaise, vertigo, headache, intensive flushing of the face, perspiration, increase in the depth of respiration, increase in heart rate, a slight rise in blood pressure, and excessive sedation. hepatitis, probably related to an immune mechanism, has been reported infrequently. rarely, this has progressed to cirrhosis. to report suspected adverse reactions, contact oryza pharmaceuticals, inc. at 1-888-296-9383 (or fda 1-800-fda-1088) or www.fda.gov/medwatch.

Pregnancy pregnancy category c - no teratogenic effects were observed in rats when papaverine hydrochloride was administered subcutaneously as a single agent. it is not known whether papaverine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. papaverine hydrochloride should be given to a pregnant woman only if clearly needed.

Pediatric use safety and effectiveness in children have not been established.

Overdosage signs and symptoms – the symptoms of toxicity from papaverine hydrochloride often result from vasomotor instability and include nausea, vomiting, weakness, central nervous system depression, nystagmus, diplopia, diaphoresis, flushing, dizziness, and sinus tachycardia. in large overdoses, papaverine is a potent inhibitor of cellular respiration and a weak calcium antagonist. following an oral overdose of 15 g, metabolic acidosis with hyperventilation, hyperglycemia, and hypokalemia have been reported. no information on toxic serum concentrations is available. following intravenous overdosing in animals, seizures, tachyarrhythmias, and ventricular fibrillation have been reported. the oral median lethal dose in rats is 360 mg/kg. treatment – to obtain up-to-date information about the treatment of overdose, a good resource is your certified regional poison control center. telephone numbers of certified poison control centers are listed in the physician’s desk reference (pdr). in managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient. protect the patient’s airway and support ventilation and perfusion. meticulously monitor vital signs, blood gases, blood chemistry values, and other variables. if convulsions occur, consider diazepam, phenytoin, or phenobarbital. if the seizures are refractory, general anesthesia with thiopental or halothane and paralysis with a neuromuscular blocking agent may be necessary. for hypotension, consider intravenous fluids, elevation of the legs, and an inotropic vasopressor, such as dopamine or norepinephrine (levarterenol). theoretically, calcium gluconate may be helpful in treating some of the toxic cardiovascular effects of papaverine; monitor the ecg and plasma calcium concentrations. forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of papaverine hydrochloride.

Description papaverine hydrochloride, usp, is the hydrochloride of an alkaloid obtained from opium or prepared synthetically. it belongs to the benzylisoquinoline group of alkaloids. it does not contain a phenanthrene group as do morphine and codeine. papaverine hydrochloride, usp, is 6,7-dimethoxy-1- veratrylisoquinoline hydrochloride and contains, on the dried basis, not less than 98.5% of c 20 h 21 no 4 •hci. the molecular weight is 375.85. the structural formula is as shown. papaverine hydrochloride occurs as white crystals or white crystalline powder. one gram dissolves in about 30 ml of water and in 120 ml of alcohol. it is soluble in chloroform and practically insoluble in ether. papaverine hydrochloride injection, usp, is a clear, colorless to pale-yellow solution. papaverine hydrochloride, for parenteral administration, is a smooth-muscle relaxant that is available in vials containing 30 mg/ml. each vial also contains edetate disodium 0.005%. the 10 ml vials also contain chlorobutanol 0.5% as a preservative. ph may be adjusted with sodium citrate and/or citric acid. structure

Clinical pharmacology the most characteristic effect of papaverine is relaxation of the tonus of all smooth muscle, especially when it has been spasmodically contracted. papaverine hydrochloride apparently acts directly on the muscle itself. this relaxation is noted in the vascular system and bronchial musculature and in the gastrointestinal, biliary and urinary tracts . the main actions of papaverine are exerted on cardiac and smooth muscle. papaverine relaxes various smooth muscles, especially those of larger arteries; this relaxation may be prominent if spasm exists. the antispasmodic effect is a direct one and unrelated to muscle innervation, and the muscle still responds to drugs and other stimuli causing contraction. papaverine has minimal actions on the central nervous system, although very large doses tend to produce some sedation and sleepiness in some patients. in certain circumstances, mild respiratory stimulation can be observed, but this is therapeutically inconsequential. Read more...

How supplied papaverine hydrochloride injection, usp, 30 mg/ml 72516-024-25 2 ml vial packaged in boxes of 25 72516-024-10 2 ml vial packaged in boxes of 10 store at 20° to 25°c (68° to 77°f); excursions permitted to 15° to 30°c (59° to 86°f) (see usp controlled room temperature). protect from light. retain in carton until time of use. manufactured for: oryza pharmaceuticals inc. coral springs, fl 33065 revised: january 2021

Package label.principal display panel ndc 72516-024-25 papaverine hydrochloride injection, usp 60 mg/2 ml (30 mg/ml) for single use only 25 x 2 ml vials rx only each ml contains: papaverine hydrochloride 30 mg, edetate disodium 0.005% and water for injection q.s. ph may be adjusted with sodium citrate and/or citric acid. store at 20°-25°c (68°-77°f); excursions permitted to 15°-30°c (59°-86°f) (see usp controlled room temperature). protect from light retain in carton until time of use. directions for use: see package insert. manufactured for: oryza pharmaceuticals inc. coral springs, fl 33065 revised: january 2021 caton-pack of 25

Package label.principal display panel ndc 72516-024-10 papaverine hydrochloride injection, usp 60 mg/2 ml (30 mg/ml) for single use only 10 x 2 ml vials rx only each ml contains: papaverine hydrochloride 30 mg, edetate disodium 0.005% and water for injection q.s. ph may be adjusted with sodium citrate and/or citric acid. store at 20°-25°c (68°-77°f); excursions permitted to 15°-30°c (59°-86°f) (see usp controlled room temperature). protect from light retain in carton until time of use. directions for use: see package insert. manufactured for: oryza pharmaceuticals inc. coral springs, fl 33065 revised: january 2021 carton- pack of 10